NET ASSET VALUE – 31 March 2025
On the 31 March 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,947 million and NAV per share was SEK 50.56.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 456 | 5.84 | 11.6% |
| Empros Pharma | 79% | 204 | 2.62 | 5.2% |
| Xspray Pharma | 18% | 192 | 2.46 | 4.9% |
| KAHR Medical | 31% | 189 | 2.43 | 4.8% |
| Atrogi | 37% | 176 | 2.25 | 4.4% |
| Lipum | 57% | 170 | 2.17 | 4.3% |
| Xintela | 61% | 162 | 2.08 | 4.1% |
| Microbiotica | 10% | 130 | 1.66 | 3.3% |
| Geneos Therapeutics | 12% | 96 | 1.23 | 2.4% |
| Toleranzia | 66% | 79 | 1.01 | 2.0% |
| Mendus | 24% | 74 | 0.94 | 1.9% |
| AnaCardio | 14% | 69 | 0.89 | 1.8% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.69 | 1.4% |
| Synerkine Pharma | 43% | 54 | 0.69 | 1.4% |
| Vitara Biomedical | 11% | 50 | 0.64 | 1.3% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Egetis Therapeutics | 2% | 23 | 0.29 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,270 | 29.08 | 57.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.8% |
| Symcel | 31% | 174 | 2.23 | 4.4% |
| Chromafora | 31% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 48 | 0.61 | 1.2% |
| Frontier Biosolutions | 2% | 18 | 0.23 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Provell Pharmaceuticals* | 72% | 0 | 0.00 | 0.0% |
| Total | 518 | 6.64 | 13.1% | |
| Limited Partnerships, total | 85 | 1.09 | 2.2% | |
| Assets related to Portfolio companies | 262 | 3.35 | 6.6% | |
| Other assets and liabilities | 811 | 10.39 | 20.6% | |
| Net asset value | 3,947 | 50.56 | 100.0% | |
* indirect shares in Provell Pharmaceuticals